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Abstract
Purpose: To investigate the relationship between visual function and severity of early age-related macular
degeneration (AMD) and activity of neovascular (nv-) AMD.
Methods: The following data was collected from 66 eyes of 66 subjects with early AMD and 47 eyes of 47
subjects with active nv-AMD: corrected distance visual acuity (CDVA); contrast sensitivity (CS); glare disability (GD);
and retinotopic ocular sensitivity (ROS) of the central 5° of the retina, by microperimetry. Fundus photographic
grading of early AMD was performed in a masked fashion. Mean foveal thickness (MFT) was measured by spectral
domain optical coherence tomography in patients with nv-AMD.
Results: In subjects with early AMD, there was an inverse and statistically significant relationship between
measures of ROS within the central 5° of retina (including fixation) and severity of early AMD (p=0.01). In eyes with
active nv-AMD, an inverse and statistically significant relationship was observed between measures of MFT and
measures of ROS at the central 5° of retina (r=-0.34; p=0.02). No other measures, including CDVA, were
significantly related to severity of early AMD, or to MFT in nv-AMD.
Conclusion: Although ROS was cross-sectionally associated with disease severity, and inversely related to MFT,
an important determinant of need-to-treat in cases of nv-AMD, further research is required to determine the
appropriateness of ROS for monitoring early and active neovascular forms of this disease.
Keywords: Age-related macular degeneration; Visual function;
Microperimetry; Retinotopic ocular sensitivity
Introduction
Age-related macular degeneration (AMD), a degenerative condition
of the macula affecting individuals fifty years or older in most cases, is
the leading cause of blind registration in the developed world [1]. Early
AMD is characterised by large soft drusen and/or pigmentary changes,
whereas the late form of AMD can be classed as atrophic or
neovascular, the latter amenable to treatment with serial injections of
anti-VEGF therapy. AMD often affects central vision, and in its
advanced form has an adverse impact on an individual’s quality of life,
as daily tasks such as reading, driving or recognising faces are impaired
[2].
A diagnosis of AMD is determined by fundoscopic appearance of
the macula, and is graded according to the morphological findings
apparent on fundus photography. Several methods of grading AMD
across the spectrum of early and late disease have been devised, and
the grade of AMD reflects the severity of the condition, and increasing
grade of early AMD is associated with increased risk of developing the
late and visually consequential forms of the disease [3,4]. Optical
coherence tomography (OCT) findings, although valuable, have not as
yet been incorporated into any validated grading scheme, and fundus
fluorescein angiography (FFA) remains a clinical tool that informs the
decision-making process regarding treatment in cases and suspected
cases of neovascular AMD (nv-AMD).
Beyond clinical signs and morphological findings, evaluation of the
impact of disease on visual function is an important component of the
clinical assessment of patients with AMD, and represents the ultimate
subjective outcome measure for any proposed treatment.
In cases of early AMD and in cases of late AMD not involving the
fovea, measures of corrected distance visual acuity (CDVA) may not
provide a measure of daily visual experience, or of disease severity [4].
One limitation of CDVA rests on the fact that it measures the angular
resolution limits of the eye at high contrast only. Therefore, CDVA
does not capture changes in colour, contrast or other aspects of visual
perception, all of which are subject to influence by environmental (e.g.
lighting) and neurophysiological (e.g., state of retinal adaptation)
factors. It has been shown that reliance on measures of visual acuity
represent an under-appreciation of the functional visual difficulty
experienced by a patient with early AMD, [4] as well as in other
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ophthalmic pathologies, such as glaucoma, cataract and diabetic
retinopathy [5,6].
Early AMD is typically associated with a decrease in CDVA of two
letters or fewer when compared to eyes without early disease, [7] and
this observation should be viewed in the context that the test-retest
variability of measures of CDVA can be up to as much as two lines of
letters on a logMAR chart [8]. Late AMD, on the other hand, is
associated with a more profound adverse impact on CDVA
(approximately seven lines of letters), but only when signs of advanced
AMD involve the central subfields of the macula [7]. Although there is
no statistically significant difference in CDVA between subjects with
nv-AMD and subjects with geographic atrophy (GA), [7] a wider range
of CDVA has been demonstrated in eyes with GA, in spite of
comparable areas of macular tissue involved by the atrophic changes,
although, unsurprisingly and intuitively, foveal involvement was the
key predictor of CDVA in cases of GA [9]. It has also been shown that,
for eyes exhibiting comparable measures of CDVA, eyes with GA have
worse visual function, particularly for dark adaptation and reading
speed, than eyes with only drusen [10]. Similarly, lesion size in
subfoveal nv-AMD fails to explain the wide variations in CDVA in
such eyes [11]. In brief, therefore, CDVA is not a sensitive
psychophysical measure that reflects severity of disease or subjective
visual experience in cases of early AMD, or when atrophic or
neovascular AMD does not affect the fovea. The purpose of this study
was to explore psychophysical measures of visual function that might
be used clinically in addition to CDVA in cases of early or nv-AMD,
and to identify one that might be incorporated into the clinical setting.
Methods
Subjects
Baseline data were collected from 66 eyes (of 66 subjects) with early
AMD and 47 eyes of 47 subjects with active nv-AMD.
The inclusion criteria for early AMD subjects were: early AMD,
graded at the Ocular Epidemiology Group (University of Wisconsin,
Madison, USA) in at least one eye (the study eye); CDVA of ≥ 20/40 in
the study eye; no visually consequential ocular morbidity other than
early AMD. Of note, in subjects who exhibited early AMD in both
eyes, the eye with better CDVA was selected for the study.
Inclusion criteria for nv-AMD were: active nv-AMD in at least one
eye (the study eye), confirmed by FFA and OCT; CDVA of ≥ 20/100 (to
ensure participants could complete the series of visually demanding
functional tests required); no visually consequential ocular pathology
other than nv-AMD in the proposed study eye. In cases where both
eyes had active nv-AMD, the eye with the better CDVA was selected
for the study.
Visual function
The following psychophysical methods were used to assess visual
function:
Corrected distance visual acuity: Corrected distance visual acuity
was measured for the study eye monocularly, and with the patient’s
best subjective refraction, using the logMAR chart (Test Chart 2000
PRO™; Thomson Software Solutions, Hertfordshire, England) and Early
Treatment of Diabetic Retinopathy Study (ETDRS) lettersets, at a
testing distance of 4 m.
Contrast sensitivity and glare disability: Contrast Sensitivity (CS)
was measured using the sine wave grating-based Functional Vision
Analyser (FVA)™ (Stereo Optical Co. Inc, Chicago, USA). Testing was
performed under mesopic (3 candelas per square metre [cd/m2]) and
photopic (85 cd/m2) conditions. This test was repeated in a similar
manner, and under the same lighting conditions, but in the presence of
an inbuilt circumferential LED (light emitting diode) glare source (1
lux for mesopic and 10 lux for photopic glare testing) to assess glare
disability (GD) [12].
Retinotopic ocular sensitivity: Retinotopic ocular sensitivity (ROS)
was measured by microperimetry (Microperimeter MP 1; Nidek
Technologies Srl, Albignasego, Italy). ROS was measured monocularly
at a constant room illuminance of 1.5 lux, according to a previously
defined protocol [13]. The study eye was pharmacologically dilated
with one drop of guttae Tropicamide BP 1% w/v minims® (Chauvin
Pharmaceuticals Ltd, Ashton Road, 75 Harold Hill, Routond, Essex,
RM3 8SL, UK) fifteen minutes prior to the test. The other eye was
covered for the duration of the test, and the eye tracking function was
used throughout. ROS was calculated for nine stimulus locations
across the central 5° of the retina, including fixation. An integrated
infrared fundus camera (1392 × 1038-pixel resolution; 45° field of
view) allowed real-time fundus imaging on a monitor. The fixation
target and stimuli were projected onto the retina by a liquid crystal
color monitor. White monochromatic background illumination was set
at 4 apostilbs (asb; 1.27 cd/m2). Stimulus intensity could be varied on a
1 (0.1 log)–step scale from 0 to 20 dB, where 0 dB represented the
brightest luminance of 400 asb (127 cd/m2). A standard Goldmann III
stimulus size was used, with a presentation duration of 200 ms. A 4-2
staircase test strategy was used. Light stimuli were randomly presented
during the examination as in standard static perimetry.
Disease status
Early AMD: AMD was graded using colour stereoscopic 30 degree
fundus photographs, that were obtained using a ZeissVisuCam® (Carl
ZeissMeditec AG, Jena, Germany) fundus camera, and were graded at
the University of Wisconsin, Madison, USA, using the Wisconsin Age-
Related Maculopathy Grading System. A detailed description of all
grading procedures and definitions has been previously described
[14,15]. Overall findings were reported on an 11-step AREDS AMD-
severity scale.
Neovascular AMD: FFA was performed in all cases in order for a
diagnosis of nv-AMD to be established or refuted. Spectral domain
OCT was performed using a Topcon 3D OCT-1000® (version 3.0, Mark
I; Topcon Corporation, Tokyo, Japan). Centration was manually
controlled by a single operator, and unreliable data were excluded in
the analysis. The central 1 mm mean foveal thickness (MFT) was
obtained from typical ETDRS macular thickness maps [16]. The
central foveal thickness was defined as the distance between the inner
and outer boundaries of the scanned image, identified using a
validated internal algorithm, and did not include any fluid under the
retinal pigment epithelium (RPE).
Statistical analysis
One way analysis of variance, with Tukey post-hoc analysis, was
used to investigate the relationship between AMD severity and
measures of visual function in cases of early AMD. Pearson
correlations were used to investigate bivariate relationships between
measures of foveal thickness and measures of visual function in cases
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of nv-AMD. Assuming a 5% level of significance and a two-tailed test,
a sample of 66 has power of 0.92 and a sample of 47 has power of 0.8,
for detecting a correlation of 0.4.
Ethical approval for these studies was granted by the Dublin
Institute of Technology Ethics Committee, and by the Waterford
Regional Hospital Ethics Committee. Informed consent was secured
from each subject, and the research was conducted in accordance with
the principles of the Declaration of Helsinki. We certify that all
applicable institutional and governmental regulations concerning the
ethical use of human volunteers were followed during this research.
Results
Visual function and AMD status
A: Early AMD: The eight grades of early AMD were collapsed (to
facilitate statistical analysis) as follows: Group 1=grades 1 and 2
(n=12); Group 2=grades 3 and 4 (n=25); Group 3=grades 5 and 6
(n=18); Group 4=grades 7 and 8 (n=11). There was a statistically
significant and inverse relationship between measures of ROS within
the central 5° of retina (including fixation) and severity of early AMD
(p=0.01) Figure 1.
Tukey post-hoc analysis revealed that Group 4 exhibited
significantly lower ROS values than Groups 1 and 2 (p<0.05 for each),
but revealed no other significant differences. No other parameters of
visual function, including CDVA (Figure 2), were significantly related
to severity of early AMD.
B: nv-AMD: A statistically significant and inverse correlation
between measures of MFT and measures of ROS within the central 5°
of retina, including fixation, is reported (r=-0.34; p=0.02); see Figure 3
for a graphical representation of the relationship) in patients with
active nv-AMD. No other measure of visual function (including CDVA
[r=-0.247; p=0.094]) was significantly related to MFT (p>0.05, for all)
in eyes with nv-AMD.
Figure 1: The relationship between severity of early AMD and ROS
within the central 5° of the retina, including fixation. AMD: Age-
Related Macular Degeneration; ROS: Retinotopic Ocular Sensitivity.
AMD severity group defined as: group 1=grades 1 and 2; group
2=grades 3 and 4; group 3=grades 5 and 6; group 4=grades 7 and 8.
Figure 2: The relationship between severity of early AMD and
CDVA. AMD: Age-Related Macular Degeneration; AMD severity
group defined as: group 1=grades 1 and 2; group=grades 3 and 4;
group 3=grades 5 and 6; group 4=grades 7 and 8.
Figure 3: The relationship between mean foveal thickness and
retinotopic ocular sensitivity within the central 5° of the retina,
including fixation, in subjects with neovascular age-related macular
degeneration. MFT: Mean Foveal Thickness; Db: Decibels; ROS:
Retinotopic Ocular Sensitivity
Discussion
This study was designed to investigate the relationship, if any,
between psychophysical visual function and disease severity in eyes
with early AMD, or MFT in eyes with active nv-AMD.
CDVA was not associated with disease severity in eyes with early
AMD. ROS was the only measure of psychophysical function tested
that was associated with severity of early AMD, based on the AREDS
AMD-severity scale [15]. ROS was significantly lower in cases with the
most severe form of early AMD (Group 4) when compared to less
advanced forms of early AMD (Groups 1 and 2).
ROS was also related to activity of nv-AMD, reflected in the inverse
relationship observed between this parameter of visual function and
MFT, where no significant relationships were observed between MFT
and any other tests of psychophysical function. As OCT-determined
Citation: Loughman J, Sabour-Pickett S, Nolan JM, Klein B, Klein R, et al. (2015) Visual Function and Its Relationship with Severity of Early, and
Activity of Neovascular, Age-Related Macular Degeneration. J Clin Exp Ophthalmol 6: 488. doi:10.4172/2155-9570.1000488
Page 3 of 5
J Clin Exp Ophthalmol
ISSN:2155-9570 JCEO, an open access journal Volume 6 • Issue 5 • 1000488
MFT represents an important component of treatment and re-
treatment regimes in nv-AMD, the observed relationship suggests that
ROS may be more suited than CDVA to monitor visual function in
patients with active neovascular disease.
There was no statistically significant association between measures
of CS or GD and severity of early AMD or activity of nv-AMD in this
study. The results here are in conflict, therefore, with those of other
studies which suggest that CS should be included as an important
measure of visual function in early AMD, [17] and possibly as an
indicator of disease progression and treatment efficacy in nv-AMD
[18-20]. Although there is a paucity of evidence in relation to GD and
AMD, improvements in GD have been recently reported in response to
anti-VEGF therapy in patients with the neovascular form of the
condition [19]. The observed disparity between our findings and those
of previous investigators in relation to CS and GD may relate to
differences in study design and methodology, including baseline
CDVA (reasonable baseline CDVA was an inclusion criterion in the
current study), test used to determine CS and GD, or variation in
sample size.
Although CDVA remains the most commonly used test of foveal
function in AMD, it may be unsuited to monitoring the functional
changes in early AMD associated with the increasing involvement of
large soft drusen or pigmentary abnormalities and treatment efficacy
in cases of nv-AMD for a variety of reasons. First, functional losses
associated with AMD progression can promote eccentric fixation
patterns that mask the depth of visual loss when only CDVA is
measured, [21] as foveal fixation is maintained in only a small
percentage of individuals with reduced CDVA, [22] which may
account, at least in part, for the under-appreciation of visual
impairment experienced by patients with AMD when using CDVA
[23]. Second, CDVA provides an assessment of photopic, and therefore
exclusively cone-mediated, visual function. It is known, however, that
rod function is more severely impaired than cone function in early
AMD [24,25]. Third, CDVA probes only a small portion of an
individual’s spatial vision, restricted to high frequency aspects only,
and is thus incapable of detecting clinically important functional
changes at moderate and low spatial frequencies [26]. The combined
effect of these limitations is such that CDVA does not provide a
comprehensive measure of visual experience, and is unlikely to capture
fully, the functional and structural changes which affect
photoreceptors, the RPE, Bruch’s membrane and the choriocapillaris in
eyes with AMD.
Further, microperimetry allows investigators to accurately assess the
relationship between functional and structural changes associated with
disease and disease treatment, reflected in the findings reported here.
No study, to our knowledge, has reported on the relationship between
ROS (or CS or GD) with respect to severity of early AMD, using a
validated system such as the Wisconsin age-related maculopathy
grading scale. However, a range of studies have looked at the
relationship between morphological features at the macula and ROS in
cases of AMD. Lower ROS in subjects with early AMD, when
compared with age-matched controls, has been reported by previous
investigators, while ROS over individual druse has been shown to be
significantly lower than adjacent retinal areas without underlying
druse [27]. For example, it has been shown that in subjects with early
AMD, ROS is reduced in areas overlying drusen and/or pigmentary
abnormalities, despite the presence of good CDVA (20/20), and this
observed reduction in sensitivity was even greater when both types of
lesions were present [28].
An association appears to exist between ROS and central retinal
thickness in patients with nv-AMD, prompting the view that ROS may
be a more appropriate means to assess central visual function than
conventional CDVA in persons with nv-AMD [29]. In this respect, our
findings are consistent with previous observations of a significant and
inverse relationship between improvements in ROS (within the central
10° of fixation) and changes in foveal thickness, but where significant
improvements in CDVA were not observed, following photodynamic
therapy in patients with nv-AMD [30]. RPE lesion area (area of disease
defined as the site presenting a significant deviation in RPE contour at
the location of the sub-retinal disease) also relates inversely to central
ROS (but not to CDVA) in patients with nv-AMD undergoing anti-
VEGF therapy [31].
Although the study was appropriately powered from a statistical
perspective, the small sample size does represent a limitation of our
study. In particular, the low numbers of subjects across each grade of
early AMD required that the eight grades be grouped for the purposes
of statistical analysis. Statistically significant relationships did emerge,
however, which could prove stronger in a larger sample. The failure to
measure (or correct for) features relating to implanted or crystalline
lenses represents a further limitation of this study given the potential
impact of variable lenticular light scatter and transmission on visual
function. The cross-sectional nature of the study also limits the
interpretation of our findings, and, despite the relationships that
emerged in our analysis, they provide no real insight into the
prognostic and long term monitoring capacity of ROS relative to
conventional techniques. These shortcomings need to be addressed in
any further attempt to evaluate the potential role of alternatives to
CDVA for AMD patients in the clinical setting.
In summary, and although we have shown a cross-sectional
relationship between ROS and severity of early AMD, and between this
parameter of visual function and MFT in cases of nv-AMD, there
remains a need to show longitudinally that ROS is a sensitive and
clinically meaningful measure, and one that is independent of CDVA,
before it can be used in clinical practice as a prognostic indicator for
patients with early AMD. Nevertheless, our findings do suggest that
this is an area of research that should not be ignored.
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